Relapsed and/or Refractory Multiple Myeloma

Oncology
5
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

Takeda
NINLAROApproved
ixazomib
Takeda
oral2015

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
1
IxazomibPhase 41 trial
IxazomibN/A1 trial
Active Trials
NCT03433001Completed295Est. Jun 2021
NCT03416374Completed45Est. May 2021
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ElotuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01632150Completed51Est. Mar 2016
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-490Phase 1/21 trial
Active Trials
NCT05719701Recruiting80Est. Dec 2025
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 420Phase 11 trial
Active Trials
NCT03836053Terminated23Est. Apr 2022
Oncopeptides
OncopeptidesSweden - Stockholm
1 program
Melphalan FlufenamideN/A1 trial
Active Trials
NCT04534322Approved For Marketing

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaIxazomib
AbbVieElotuzumab
InnoCareICP-490
AmgenAMG 420
TakedaIxazomib

Clinical Trials (6)

Total enrollment: 494 patients across 6 trials

NCT03416374TakedaIxazomib

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Start: Feb 2018Est. completion: May 202145 patients
Phase 4Completed
NCT01632150AbbVieElotuzumab

Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Start: May 2012Est. completion: Mar 201651 patients
Phase 2Completed
NCT05719701InnoCareICP-490

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Start: Mar 2023Est. completion: Dec 202580 patients
Phase 1/2Recruiting
NCT03836053AmgenAMG 420

Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Start: Mar 2019Est. completion: Apr 202223 patients
Phase 1Terminated
NCT04534322OncopeptidesMelphalan Flufenamide

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

N/AApproved For Marketing
NCT03433001TakedaIxazomib

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Start: Apr 2018Est. completion: Jun 2021295 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
15m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
15m ago

Office Administrator

SystImmune
15m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
25m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
29m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
29m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 494 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)